continued review update of our an the followed begin you, Richard. progress by a plans deep of Thank commercialization I pipeline. for our of will Mirataz, with today's overview
be will the an is approval. our medication depth proprietary and as approval of Of our a now transdermal our to team development able the demonstrates to This you in incredible very well. unveil less than first of course, years develop five feat To begin congratulating our talents like team. we first-in-class and capabilities and commercial I'd KindredBio to talented of by research on team FDA our investigators
As management am commercialization commercial we out in our in addition to our to and have you've our veterinary we customer quite heard members me our From you leaders, describe XX this for commercial thought recruited preparing previous departments our relationship operations our operations that team to system establishing sales pleased time. veterinary some affairs judiciously quarterly engagement customer base. mapping organization. tell members, have and calls, to been I with Today, so in designing for affairs
years This an initial XXX We most-experienced deep with the experience relationships, hired comes training over conducted and specifically corporate team. of customer across team to management, more. KindredBio managing in XX of the have talent our in industry a distributor to accounts, the and average team distribution, have interviews curated include and and talent we the practice top with
corporate prior accounts will accounts, other that team and reach specialty our hospitals call FDA distributors Now we their key have to shipping. to for begin centers and Mirataz, approval train to and out product the
reps Our take will customers distributor two preorders in and direct sales weeks. from next begin the reps to
to to approximately our two months. update of product the our ship working printing and packaging in contract manufacturer complete are We with and intend
very enough is launch orders We want clinics initial stock many to for products, so and customer to supply material our orders plan the be to will with Our stocking important. enough as anticipated penetration at to distributors, try have reorders.
$XX set our have tube. at price for introductory Mirataz per We
work is We owners, all as penetration by both long have to lot veterinarians maximum usage as owners, price done of well reach a the and revenue to best cat and this and know pricing maximize with term. sensitivity
details penetration look our and call. quarterly forward over orders next price during We regarding likely will this to providing We increase stocking initial time.
report come able to are XX-day distributors shipments the reorders, days to revenue or be stocking should initial to made launch after the initial or distributor will in XX one-time the this We upon within customers, period. they
Zimeta in horses. control fever discuss product let's for Now our the IV, of
section. KindredBio that informed additional have we has for As previously, for technical we the technical no approval us reported they have questions safety sections. CMC our FDA and FDA effectiveness on
of of The these provider. July. manufacturer, scheduled resolution are contract API is in resolution. findings the provider inspection which and the has additionally, API our from We And a responded anticipates are already to our we preapproval the timely awaiting findings to awaiting inspection
Following file application Zimeta section. successful inspections, our drug of IV new CMC animal technical the upon the we will completion
I our will updates to programs. deep of turning Now some on pipeline, provide the key
As KindredBio. we have for effectiveness has for Zimeta reported, Oral with This study been results. pivotal consecutive the positive the pivotal positive field third trial completed was
Target that to well As be is proprietary also use to upon was of a drug expand reminder, completed, success The oral and Safety Oral Study the found and is gel Zimeta is IV. tolerated. the drug expected of Animal the Zimeta the build a
in and product of in manufacturer. FDA to submission our We with the discussion regarding commercial are process our are transferring the
with atopic treatment As Richard taking outlined, a biologics. multipronged a approach towards promising of portfolio we are the dermatitis
fully have canonized the including We a IL-XX more dermatitis, from in before to antibody, and atopic IL-X/IL-XX a pilot initiating studies of IL-XX or this hope a of pilot process these of report the field initiated for We or canine SINK one fully molecules antibody studies effectiveness several canonized data year. for molecule. end
protein to enhanced continuing half-life long-acting study has to erythropoietin. specially EpoCat that of our recombinant feline endogenous is version feline enroll prolonged epoCat. by We compared of been engineers our protein our field engineered a pilot effectiveness a with are
once-monthly the the gastric been of pilot KIND-XXX treatment KIND-XXX allow PK tolerated. suggests dosing. has a field well The was data completed, ulcers for sufficiently that may long of equine have very Our molecule study for and half-life to
septic the have We dose initiated The have the advanced end support which will has and studies. to therapy. antibody have field and further the the intend the to FDA-approved on foaling an data regarding need KIND-XXX, a anti-TNF finding completed and studies our anti-TNF FDA studies is field we has been development. and have the By call, candidates been the palatability unmet review been completed into no pilot sick field antibody study pivotal which with results, our important currently based medical monoclonal studies fully foals Since following during to in targeting for second this up of there expect XXXX of The discussion pilot efficacy formulation development pilot X optimized we range data into have monoclonal completed XX% completed. or Sepsis for season, of mortality and results. last we quarter, the and of positive the assuming can determine enrollment cause one field study with continue formulations formulation equinized study move plan. is foals
signs completed palatability management Lastly, tolerability pilot as we field equine of for with reported, metabolic the a associated study we previously syndrome. oral have clinical of the assessing KIND-XXX and
We have pilot a optimized initiated have field effectiveness the study. and formulation
anticipate We dermatitis. initial front, acquired by atopic to facility in for the pleased to manufacturing we XXXX support in manufacturing our our switching that started needs to monoclonal support Kansas Now you have our to we tell fully be that for am antibodies of our to biologics August manufacturing XXXX. lines construction Elwood, completed I construction
this you has could as the team So from productive. been incredibly see KindredBio update,
We multiple to advance plant complement in out in precommercialization are manufacturing of product prepared to pipeline candidates to fully Zimeta and our efficiently complete plant to a San Francisco. build state-of-the-art commissioned well our launch work Mirataz, to to successful IV, support in diligently our and support a Kansas
our to will to of update call forward look to XXXX positioned keeping Wendy XXXX, now We achievements. I financials. to the a and are quarter With turn first have an apprised productive we that, and very well on you our over successful provide
